Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
株価
$0.1559364
最終同期: 2026-09-18
時価総額
$195.17K
変化(1日)
6.60%
変化(1年)
-30.91%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)の利益
Sep 2025 時点の利益 TTM: $-2.06M
Fusion Antibodies plc の最新の財務報告によると、同社の現在の利益は $-2.06M です。2024 年には $-2.89M の利益を上げ、これは 2023 年の利益 $-3.53M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Fusion Antibodies plc の利益の推移(2013 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -256,061.35%
US
$1.95B -94,754.12%
NL
$-3.09B 149,694.82%
US
$-4.02B 194,783.51%
AU
- -
CH